Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EV/FCF ratio high or low?
The EV/FCF ratio of 82.40x is 24% below its estimated 1-year average of 109.02x, near the low end of its estimated 1-year range (82.40x–141.29x).
As of 2026-10-06T12:50:32.061Z.
Calculation as of: 2026-10-06T12:50:32.061Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: b9d80053686f16721d19c62710da14dda18ff2c6e5fba2adc15c1c35f0ac96a2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
82.40x
EV/FCF RATIO AVG TTM
N/A
EV/FCF RATIO AVG 3Y
N/A
EV/FCF RATIO AVG 5Y
N/A
EV/FCF RATIO AVG 10Y
N/A
EV/FCF RATIO AVG 15Y
N/A
EV/FCF RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
24.36x
median of 144 covered companies
CURRENT VS SECTOR MEDIAN
+238.26%
vs the sector median at left
Arcutis Biotherapeutics, Inc.
Market Cap
$3.15B
EV/FCF Ratio
82.40x
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.16B
EV/FCF Ratio
N/A
TTM Avg
15.31x
3Y Avg
19.99x
5Y Avg
19.99x
Market Cap
$3.09B
EV/FCF Ratio
N/A
TTM Avg
34.40x
3Y Avg
34.40x
5Y Avg
34.40x
Market Cap
$2.87B
EV/FCF Ratio
41.29x
TTM Avg
54.95x
3Y Avg
90.13x
5Y Avg
90.13x
Market Cap
$3.44B
EV/FCF Ratio
17.96x
TTM Avg
24.95x
3Y Avg
51.13x
5Y Avg
51.13x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | $3.15B | 82.40x | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | N/A | 15.31x | 19.99x | 19.99x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | N/A | 34.40x | 34.40x | 34.40x |
| Enliven Therapeutics, Inc. (ELVN)vs › | $3.25B | N/A | N/A | N/A | N/A |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 41.29x | 54.95x | 90.13x | 90.13x |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 53.99x | 69.55x | 89.95x | 89.95x |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.44B | 17.96x | 24.95x | 51.13x | 51.13x |
| Celcuity Inc. (CELC)vs › | $3.59B | N/A | N/A | N/A | N/A |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 25.90x | 31.01x | 94.23x | 120.63x |
EV/FCF
82.4x
P/FCF
80.3x
FCF Yield
1.24%
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EV/FCF RATIO |
|---|---|
| 2026-10-05 | 89.34x |
| 2026-10-02 | 89.38x |
| 2026-10-01 | 89.83x |
| 2026-09-30 | 93.79x |
| 2026-09-29 | 94.90x |
| 2026-09-28 | 96.91x |
| 2026-09-25 | 95.49x |
| 2026-09-24 | 93.23x |
| 2026-09-23 | 93.61x |
| 2026-09-22 | 98.47x |
| 2026-09-21 | 92.15x |
| 2026-09-18 | 90.14x |
| 2026-09-17 | 93.89x |
| 2026-09-16 | 92.78x |
| 2026-09-15 | 83.65x |
| 2026-09-14 | 86.29x |
| 2026-09-11 | 84.97x |
| 2026-09-10 | 83.20x |
| 2026-09-09 | 84.80x |
| 2026-09-08 | 86.70x |
| 2026-09-04 | 85.00x |
| 2026-09-03 | 84.17x |
| 2026-09-02 | 84.83x |
| 2026-09-01 | 84.48x |
| 2026-08-31 | 85.25x |
| 2026-08-28 | 84.59x |
| 2026-08-27 | 88.37x |
| 2026-08-26 | 89.31x |
| 2026-08-25 | 88.34x |
| 2026-08-24 | 88.06x |
| 2026-08-21 | 89.10x |
| 2026-08-20 | 90.04x |
| 2026-08-19 | 93.89x |
| 2026-08-18 | 94.17x |
| 2026-08-17 | 90.94x |
| 2026-08-14 | 92.95x |
| 2026-08-13 | 91.70x |
| 2026-08-12 | 93.26x |
| 2026-08-11 | 93.09x |
| 2026-08-10 | 92.02x |
| 2026-08-07 | 89.83x |
| 2026-08-06 | 93.79x |
| 2026-08-05 | 133.22x |
| 2026-08-04 | 128.08x |
| 2026-08-03 | 127.64x |
| 2026-07-31 | 132.06x |
| 2026-07-30 | 137.50x |
| 2026-07-29 | 136.87x |
| 2026-07-28 | 139.56x |
| 2026-07-27 | 136.77x |
| 2026-07-24 | 134.42x |
| 2026-07-23 | 134.32x |
| 2026-07-22 | 137.06x |
| 2026-07-21 | 138.79x |
| 2026-07-20 | 135.28x |
| 2026-07-17 | 139.90x |
| 2026-07-16 | 136.29x |
| 2026-07-15 | 136.49x |
| 2026-07-14 | 131.82x |
| 2026-07-13 | 133.31x |
| 2026-07-10 | 136.29x |
| 2026-07-09 | 141.29x |
| 2026-07-08 | 139.95x |
| 2026-07-07 | 135.96x |
| 2026-07-06 | 128.27x |
| 2026-07-02 | 127.02x |
| 2026-07-01 | 127.16x |
| 2026-06-30 | 128.99x |
| 2026-06-29 | 131.58x |
| 2026-06-26 | 132.74x |
| 2026-06-25 | 131.25x |
| 2026-06-24 | 134.52x |
| 2026-06-23 | 129.23x |
| 2026-06-22 | 131.10x |
| 2026-06-18 | 128.94x |
| 2026-06-17 | 128.99x |
| 2026-06-16 | 126.35x |
| 2026-06-15 | 125.91x |
| 2026-06-12 | 120.15x |
| 2026-06-11 | 121.15x |
| 2026-06-10 | 114.62x |
| 2026-06-09 | 112.50x |
| 2026-06-08 | 106.50x |
| 2026-06-05 | 105.01x |
| 2026-06-04 | 108.47x |
| 2026-06-03 | 105.58x |
| 2026-06-02 | 102.89x |
| 2026-06-01 | 106.16x |
| 2026-05-29 | 106.11x |
| 2026-05-28 | 106.01x |
| 2026-05-27 | 104.62x |
| 2026-05-26 | 104.43x |
| 2026-05-22 | 103.23x |
| 2026-05-21 | 103.95x |
| 2026-05-20 | 101.35x |
| 2026-05-19 | 96.69x |
| 2026-05-18 | 99.24x |
| 2026-05-15 | 105.44x |
| 2026-05-14 | 106.64x |
| 2026-05-13 | 107.22x |
| 2026-05-12 | 102.41x |
| 2026-05-11 | 105.05x |
| 2026-05-08 | 104.72x |
| 2026-05-07 | 102.27x |
